TrialInternational immunopharmacology2018

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.

Richard P Tobin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.